A 2-Years Comparative Analysis of Tirzepatide, Semaglutide, Qsymia, Contrave, and Phentermine on Ocular Health in Individuals with Obesity: A Propensity-Score Matched Cohort Study DOI Creative Commons
Pen‐Hua Su, Yu‐Nan Huang,

Jo-Ching Chen

et al.

Research Square (Research Square), Journal Year: 2025, Volume and Issue: unknown

Published: Feb. 4, 2025

Abstract This landmark propensity-score matched study examined ocular outcomes of modern anti-obesity medications in nearly 5 million non-diabetic individuals with obesity. Through analysis TriNetX US network data, we discovered that Tirzepatide significantly reduced cataract risk versus other treatments, showing a striking 59% lower compared to Semaglutide (HR: 0.41, 95% CI: 0.19–0.85). users experienced markedly fewer visual disturbances than those on Contrave 0.58, 0.41–0.82) or Phentermine 0.62, 0.46–0.82). Both GLP-1 receptor agonists demonstrated protection against age-related cataracts, exceptional benefits 0.17, 0.07–0.42). While these protective effects remained robust across patient subgroups, Tirzepatide's diminished impaired kidney function. Multiple sensitivity analyses and negative controls validated compelling findings.

Language: Английский

4. Comprehensive Medical Evaluation and Assessment of Comorbidities: Standards of Care in Diabetes—2025 DOI
Nuha A. ElSayed, Rozalina G. McCoy, Grazia Aleppo

et al.

Diabetes Care, Journal Year: 2024, Volume and Issue: 48(Supplement_1), P. S59 - S85

Published: Dec. 9, 2024

Language: Английский

Citations

18
Estimating direct tissue effects versus weight loss effects of incretin-based drugs for obesity on various chronic conditions DOI
Naveed Sattar, Matthew M.Y. Lee

The Lancet Diabetes & Endocrinology, Journal Year: 2025, Volume and Issue: unknown

Published: Jan. 1, 2025

Language: Английский

Citations

3
GLP-1 and the Neurobiology of Eating Control: Recent Advances DOI Creative Commons
Lauren A. Jones, Daniel I. Brierley

Endocrinology, Journal Year: 2025, Volume and Issue: unknown

Published: Jan. 15, 2025

Abstract Obesity is now considered a chronic relapsing progressive disease, associated with increased all-cause mortality that scales bodyweight, affecting more than 1 billion people worldwide. Excess body fat strongly excess energy intake, and most successful anti-obesity medications (AOMs) counter this positive balance through the suppression of eating to drive weight loss. Historically, AOMs have been characterised by modest loss side effects which are compliance-limiting, in some cases life-threatening. However, field obesity pharmacotherapy has entered new era based on analogues gut hormone neuropeptide glucagon-like peptide-1 (GLP-1). The latest versions these drugs elicit unprecedented levels clinical trials, starting be substantiated real-world usage. Notably, reduce primarily reducing via activation GLP-1 receptor multiple sites action CNS, although relevant action, neural circuits recruited remain contentious. Here we provide targeted synthesis recent developments neurobiology, highlighting studies advanced our understanding how signalling modulates eating, identify open questions future challenges believe still need addressed aid prevention and/or treatment obesity.

Language: Английский

Citations

2
Glucagon like peptide-1 (GLP-1) agonists and cardiometabolic protection: historical development and future challenges DOI Creative Commons
Francisco Westermeier, Enrique Z. Fisman

Cardiovascular Diabetology, Journal Year: 2025, Volume and Issue: 24(1)

Published: Jan. 29, 2025

Language: Английский

Citations

2
The Efficacy of Glucagon-like Peptide-1 (GLP-1) Receptor Agonists for Insufficient Weight Loss or Regain After Metabolic/Bariatric Surgery: A Systematic Review and Meta-analysis DOI

Joanne Kellett,

Sara Soliman, Alicia Podwójniak

et al.

Obesity Surgery, Journal Year: 2025, Volume and Issue: unknown

Published: Feb. 5, 2025

Language: Английский

Citations

2
Obesity: Recent Advances and Future Perspectives DOI Creative Commons
Miodrag Janić, Andrej Janež, Mohamed El‐Tanani

et al.

Biomedicines, Journal Year: 2025, Volume and Issue: 13(2), P. 368 - 368

Published: Feb. 5, 2025

As reported in the World Obesity Atlas 2024 by Federation, projections for 2035 suggest that more than 1 [...]

Language: Английский

Citations

2
Once-Weekly Semaglutide in Adults With Alcohol Use Disorder DOI
Christian S. Hendershot, Michael P. Bremmer, Michael B. Paladino

et al.

JAMA Psychiatry, Journal Year: 2025, Volume and Issue: unknown

Published: Feb. 12, 2025

Importance Preclinical, observational, and pharmacoepidemiology evidence indicates that glucagon-like peptide 1 receptor agonists (GLP-1RAs) may reduce alcohol intake. Randomized trials are needed to determine the clinical significance of these findings. Objective To evaluate effects once-weekly subcutaneous semaglutide on consumption craving in adults with use disorder (AUD). Design, Setting, Participants This was a phase 2, double-blind, randomized, parallel-arm trial involving 9 weeks outpatient treatment. Enrollment occurred at an academic medical center US from September 2022 February 2024. Of 504 potential participants assessed, 48 non–treatment-seeking AUD were randomized. Intervention received (0.25 mg/week for 4 weeks, 0.5 1.0 mg week) or placebo weekly clinic visits. Main Outcomes Measures The primary outcome laboratory self-administration, measured pretreatment posttreatment (0.5 mg/week). Secondary exploratory outcomes, including prospective changes craving, assessed Results Forty-eight (34 [71%] female; mean [SD] age, 39.9 [10.6] years) Low-dose reduced amount consumed during self-administration task, medium large effect sizes grams (β, −0.48; 95% CI, −0.85 −0.11; P = .01) peak breath concentration −0.46; −0.87 −0.06; .03). Semaglutide treatment did not affect average drinks per calendar day number drinking days, but significantly −0.41; −0.73 −0.09; .04) −0.39; .01), also predicting greater reductions heavy over time relative 0.84; 0.71 0.99; .04). A significant treatment-by-time interaction indicated predicted cigarettes subsample individuals current cigarette −0.10; −0.16 −0.03; .005). Conclusions Relevance These findings provide initial low-dose can some justifying larger GLP-1RAs disorder. Trial Registration ClinicalTrials.gov Identifier: NCT05520775

Language: Английский

Citations

2
Real-World Evidence Assessment of the Risk of Nonarteritic Anterior Ischemic Optic Neuropathy in Patients Prescribed Semaglutide DOI
David C. Klonoff,

Gavin Hui,

Saurabh Gombar

et al.

Journal of Diabetes Science and Technology, Journal Year: 2024, Volume and Issue: 18(6), P. 1517 - 1518

Published: July 30, 2024

Language: Английский

Citations

11
Considering the use of GLP-1 receptor agonists in women with obesity prior to pregnancy: a narrative review DOI Creative Commons
Sarah Price, Alison Nankervis

Archives of Gynecology and Obstetrics, Journal Year: 2025, Volume and Issue: 311(5), P. 1241 - 1247

Published: Jan. 7, 2025

Abstract Purpose Metabolic disease, including obesity and type 2 diabetes, are amongst the most significant health issues facing women of reproductive age. To date, no antenatal weight management tools have reduced risk adverse outcomes for with their offspring, resulting in a shift focus to pre-conception period. Although not yet recognised international guidelines, glucagon-like peptide-1 receptor agonists (GLP-1 RAs) being increasingly used prior conception. Methods A literature search PubMed, Medline, Embase databases identified relevant articles describing use GLP-1 RAs during pregnancy. Papers were selected based on relevance originality, clinical trials, large observational studies meta-analyses preferentially included. Results This narrative review summarises mechanism action effects observed non-pregnant adults. It synthesises available data from human animal regarding safety efficacy pregnancy, consequences inadvertent drug exposure early In considering need balance risks metabolic disease posed by exposure, it highlights areas where further research is needed guide decision-making. Conclusion may role facilitating loss improving However, there currently insufficient evidence demonstrate that this class drugs pregnancy improves outcomes.

Language: Английский

Citations

1
Efficacy and Safety of Efpeglenatide in Patients With Type 2 Diabetes and Obesity: A Systematic Review DOI Open Access

Neha Narayan,

Tejaswi Vadde,

Maharshikumar Sandesara

et al.

Cureus, Journal Year: 2025, Volume and Issue: unknown

Published: Jan. 7, 2025

Efpeglenatide, a novel long-acting glucagon-like peptide-1 receptor agonist (GLP-1 RA), shows promise for the treatment of type 2 diabetes mellitus (T2DM) and obesity. This systematic review evaluated efficacy safety efpeglenatide in patients with T2DM Literature searches PubMed, Scopus, Web Science focused on randomized controlled trials (RCTs), cohort studies, case-control longitudinal observational studies from 2019 to 2024. Eight met inclusion criteria. The findings these consistently indicate that significantly reduces hemoglobin A1C (HbA1C), fasting plasma glucose (FPG), body weight Once-weekly dosing offers convenient alternative daily GLP-1 RAs potentially improves adherence. Efpeglenatide also provides cardiovascular renal benefits, particularly high-risk patients, thus providing comprehensive option. profile is similar other RAs, mild-to-moderate gastrointestinal side effects being most common low risk hypoglycemia, especially not using insulin or sulfonylureas. Most show bias enhanced reliability. However, limitations include need long-term data variations study design. Future research should focus outcomes, safety, improvements quality life fully assess benefits efpeglenatide. In conclusion, promising obesity, offering effective glycemic control, reduction, favorable profile, dosing.

Language: Английский

Citations

1